Lung Cancer
Febrile neutropenia risk is high with vinorelbine/gemcitabine/cisplatin therapy
Published in Cancer Weekly, February 25th, 2003
Researchers in Japan "conducted a phase II trial of triplet chemotherapy consisting of vinorelbine, gemcitabine, and cisplatin in patients with advanced non-small cell lung cancer to assess its efficacy and toxicity. Thirty-three patients with chemotherapy-naive stage IIIB disease (n=8), stage IV disease (n=23), or recurrence after surgical resection (n=2) were given intravenous infusions of vinorelbine 25 mg/m2, gemcitabine 1000 mg/m2, and cisplatin 40 mg/m2 on days 1 and 8 at 3 week intervals. There were 16 partial responses, and the objective response rate was 48% (95% CI 31-66%).
"The median survival time was 13.5 months (95% CI...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-02-25)
More Articles from Cancer Weekly
- Developmental Biology
First step along possible new avenue of cancer research reported - Lung Cancer
Chemical cousin of vitamin A restores gene function in former smokers - Adrenal Tumors
Molecular mechanisms underlying the pathogenesis being unraveled - Brain Cancer
Macrophage migration inhibitory factor key to vascularity of glioblastoma - Carcinoid Cardiopathy
Metastatic ileum carcinoid blockage of the heart conducting system - Cell Biology
Scientists unlock secrets of cancer's eternal youth - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
